Amylyx Pharmaceuticals appoints rare disease specialist as UK and Ireland General Manager

Amylyx Pharmaceuticals appoints rare disease specialist as UK and Ireland General Manager

Andy Caldwell brings a deep commitment to the rare disease community and 30 years of life science leadership

London, February 26, 2024 – Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”), a global pharmaceutical company dedicated to the discovery and development of new treatments for neurodegenerative diseases, today announced the appointment of Andrew Caldwell to General Manager UK and Ireland. He joins Amylyx with more than 30 years of life science industry experience including a decade spent in the commercialisation of rare and specialised disease therapies in the UK and Ireland.

“We are thrilled to have Andrew join us on our mission to end the suffering caused by neurodegenerative diseases. His unique experience and knowledge will help solidify our presence in the region, with the aim to build strong collaboration with the community to ensure people living with neurodegenerative disease can benefit from advances in care and therapeutic options in the UK and Ireland,” said Stéphanie Hoffmann-Gendebien, Head, General Manager EMEA at Amylyx Pharmaceuticals.

Andrew has previously established and grown UK and Ireland-focused business entities for neurodegenerative disease specialist Orphazyme, and Akcea Therapeutics. He was also a former commercial lead for Alexion Pharmaceuticals and a core member of Merck Serono’s UK senior leadership team. He was involved in the strategic development of the company’s UK business with specific responsibility for the commercialisation of its Neurology and Endocrinology business.

“As someone who has worked in the field of rare and ultra-rare diseases for over a decade, I’m deeply committed to supporting people who live with these devastating conditions and the wider community of people who care for them,” said Andrew. “Working as part of the Amylyx EMEA team, I’m determined to help advance our position in motor neurone disease, which has had no new treatment option in Europe for more than 25 years. Alongside this, I’m excited to be part of Amylyx’ progress in addressing other neurodegenerative diseases.”

About Motor Neurone Disease

Motor neurone disease (MND, also known as amyotrophic lateral sclerosis or ALS) is a relentlessly progressive and fatal neurodegenerative disorder caused by motor neurone death in the brain and spinal cord. Motor neurone loss in MND leads to deteriorating muscle function, the inability to move and speak, respiratory paralysis and eventually, death. More than 90% of people with MND have sporadic disease, showing no clear family history. More than 30,000 people in Europe (European Union and United Kingdom) are estimated to live with MND. Their average life expectancy is 2-5 years after symptom onset.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada, EMEA, and Japan. For more information, visit amylyx.eu and follow us on LinkedIn and X, formerly known as Twitter. For investors, please visit investors.amylyx.com.